Core Insights - SpringWorks Therapeutics, Inc. has appointed Martin Mackay, Ph.D. to its Board of Directors, bringing over 30 years of experience in pharmaceutical and biotech R&D [1][2] - Dr. Mackay's expertise in rare diseases and leadership roles at major companies like Pfizer, AstraZeneca, and Alexion will be valuable for SpringWorks as it expands its pipeline [2] - SpringWorks is focused on developing life-changing medicines for severe rare diseases and cancer, with its first FDA-approved therapy being OGSIVEO® (nirogacestat) for desmoid tumors [3] Company Overview - SpringWorks Therapeutics is a commercial-stage biopharmaceutical company that applies a precision medicine approach [3] - The company has a diversified pipeline targeting solid tumors and hematological cancers, with programs at various stages from preclinical to advanced clinical trials [3] - SpringWorks has established collaborations with industry and academic innovators to enhance its portfolio and create more solutions for patients [3] Leadership and Experience - Dr. Mackay is a co-founder and Executive Chairman of Rallybio, a clinical-stage biotechnology company focused on severe rare diseases [2] - His previous roles include Executive Vice President at Alexion and President of R&D at AstraZeneca, where he led global R&D functions [2] - Dr. Mackay has held various positions at Pfizer, including Senior Vice President of Worldwide Development, contributing to a wide range of investigational medicines [2] Educational Background - Dr. Mackay holds a First-Class Honours Degree in microbiology from Heriot-Watt University and a Ph.D. in molecular genetics from the University of Edinburgh [2]

STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven in ...

STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, August 7, 2024 to report its second quarter financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by ph ...

For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube. Samantha Hilson Sandler Senior Director, Investor Relations Phone: 203-461-5501 Email: samantha.sandler@springworkstx.com STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a. ...

Earlier this month, the company completed the new drug application (NDA) submission for its investigational MEK inhibitor, mirdametinib, which is being developed for the treatment of neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN), in pediatric and adult patients. SWTX plans to file a marketing application with the European Medicines Agency seeking approval for mirdametinib for the treatment of children and adults with NF1-PN later in the second half of 2024. Following the FDA nod, not ...

The NDA filing was based on data from the pivotal phase IIb ReNeu study, which evaluated mirdametinib in patients aged two years and above with NF1-associated PN causing significant morbidity. SpringWorks Therapeutics, Inc. (SWTX) announced that it has completed the submission of a new drug application ("NDA") for its investigational MEK inhibitor, mirdametinib, being developed for the treatment of neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN), in pediatric and adult patients. The pr ...

NEW YORK, July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. Why Your Participation Matters: For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. Contacts: Kuehn Law, P ...

"We are pleased to be one step closer towards our goal of bringing mirdametinib to patients with NF1-PN in the U.S. and believe that our ReNeu data support the potential for mirdametinib to be a differentiated and best-inclass therapy for both children and adults living with this devastating disease," said Saqib Islam, Chief Executive Officer of SpringWorks. "We look forward to working closely with the FDA throughout the review process and also plan to file for regulatory approval in the European Union late ...

The NDA submission includes data from the pivotal Phase 2b ReNeu trial, which evaluated mirdametinib in patients ≥ 2 years of age with NF1-associated PN causing significant morbidity. Results were presented in an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting and demonstrated that mirdametinib treatment resulted in significant objective response rates confirmed by blinded independent central review, deep and durable responses, improvement in pain and health-related qualit ...

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference, taking place in Miami, Florida on Tuesday, June 11, 2024 at 2:00 p.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the comp ...